Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

EDX Medical Group Plc in Focus as FTSE AIM All-Share Investors Weigh the Next Growth Test (LSE:EDX)

The immediate point of attention is investor attention on commercial test adoption, laboratory throughput and the ability to translate clinical capability into revenue. This matters because it gives the market a current reference point for assessing management’s priorities and the timetable for the next …

Ankur Sharma | 11 November 2026

FTSE AIM All-Share: Futura Medical (LSE:FUM) Enters the Spotlight as Healthcare Momentum Builds

LSE:FUM is being watched for the next measurable operational, financial, project or commercial milestone.

Ankur Sharma | 11 November 2026

FTSE AIM All-Share Healthcare Watch: Fusion Antibodies Remains Focused on Commercialising Its Science [LSE:FAB]

• Investors are watching execution, cash generation, funding visibility and the timing of the next milestone.

Ankur Sharma | 11 November 2026

CellBXHealth Plc in Focus as FTSE AIM All-Share Investors Weigh the Next Growth Test (LSE:CLBX)

The immediate point of attention is investors’ focus on commercial validation, funding and the evidence that its technology can gain repeat use. This matters because it gives the market a current reference point for assessing management’s priorities and the timetable for the next material …

Ankur Sharma | 11 November 2026

FTSE AIM All-Share Biotech Spotlight: Coiled Therapeutics Draws Attention as Development Risk Meets Ambition [LSE:COIL]

• Investors are watching execution, cash generation, funding visibility and the timing of the next milestone.

Ankur Sharma | 11 November 2026

FTSE AIM All-Share: Coiled Therapeutics (LSE:COIL) Enters the Spotlight as Healthcare Momentum Builds

LSE:COIL is being watched for the next measurable operational, financial, project or commercial milestone.

Ankur Sharma | 11 November 2026

FTSE AIM All-Share Focus: CRISM Therapeutics Corporation Draws Investor Attention as The Next Clinical And Funding Milestones That Can Validate The Platform (LSE:CRTX)

The latest confirmed development is central to today’s attention. The investment case is driven by clinical and technical milestones, intellectual-property development and the ability to secure partners or financing. Investor attention in biotechnology is often event-led, so trial design, regulatory engagement and cash runway …

Ankur Sharma | 11 November 2026

Why Abingdon Health Plc Is Drawing Attention on the FTSE AIM All-Share This November (LSE:ABDX)

The immediate point of attention is its October update reporting 30% revenue growth and progression to adjusted EBITDA profitability in the second half of FY26. This matters because it gives the market a current reference point for assessing management’s priorities and the timetable for …

Ankur Sharma | 11 November 2026

Agronomics Remains in Focus as Its Cellular Agriculture Portfolio Develops (LSE:ANIC)

The immediate story is about whether the latest development changes the company’s operating outlook, balance-sheet position, project timetable or strategic options. For smaller listed companies, a single contract, financing event, licence, acquisition, clinical milestone or trading update can have an outsized impact on expectations. …

Ankur Sharma | 11 November 2026

FTSE SmallCap Healthcare Focus: Anpario's Profit Growth and Buyback Keep the Market Engaged [LSE:ANP]

• Investors are watching execution, cash generation, funding visibility and the timing of the next milestone.

Ankur Sharma | 11 November 2026
Support

Hi! How can we help you today?

Loading…